Market Cap
US$85.1m
Last Updated
2019/10/23 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis.
Snowflake
Fundamentals
Flawless balance sheet and overvalued.
Share Price & News
How has Immunic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-7.8%
IMUX
3.1%
US Biotechs
0.07%
US Market
1 Year Return
n/a
IMUX
-1.6%
US Biotechs
8.9%
US Market
Return vs Industry: Insufficient data to determine how IMUX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IMUX performed against the US Market.
Shareholder returns
| IMUX | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.8% | 3.1% | 0.07% |
| 30 Day | -31.9% | 0.2% | -0.3% |
| 90 Day | -37.9% | 0.9% | -1.6% |
| 1 Year | n/a | -0.7%-1.6% | 11.3%8.9% |
| 3 Year | n/a | 18.9%14.7% | 46.3%36.8% |
| 5 Year | n/a | -1.8%-6.6% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is Immunic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
What Kind Of Shareholders Own Immunic, Inc. (NASDAQ:IMUX)?Valuation
Is Immunic undervalued compared to its fair value and its price relative to the market?
1.21x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMUX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IMUX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMUX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMUX is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Immunic forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
22.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Immunic's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Immunic performed over the past 5 years?
-163.1%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: IMUX is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.
Accelerating Growth: Unable to compare IMUX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMUX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).
Return on Equity
High ROE: IMUX has a negative Return on Equity (-36.93%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: IMUX is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: IMUX is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Immunic's financial position?
Financial Position Analysis
Short Term Liabilities: IMUX's short term assets ($39.5M) exceeds its short term liabilities ($3.1M)
Long Term Liabilities: IMUX's short term assets (39.5M) exceeds its long term liabilities (41.0K)
Debt to Equity History and Analysis
Debt Level: IMUX is debt free.
Reducing Debt: IMUX has not had any debt for past 5 years.
Balance Sheet
Inventory Level: IMUX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if IMUX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMUX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMUX has sufficient cash runway for 1.136445 years if free cash flow continues to reduce at historical rates of -45.9% each year.
Next Steps
Dividend
What is Immunic's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate IMUX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IMUX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if IMUX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMUX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMUX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Immunic's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Daniel Vitt (51yo)
2.8yrs
Tenure
Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since January 1, 2017 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG ...
Management Age and Tenure
2.8yrs
Average Tenure
Experienced Management: IMUX's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
2.8yrs
Average Tenure
51yo
Average Age
Experienced Board: IMUX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Daniel Vitt (51yo)
CEO, President & Director
- Tenure: 2.8yrs
Manfred Gröppel
Co-Founder & COO
- Tenure: 0yrs
Andreas Mühler (56yo)
Co-Founder and Chief Medical Officer
- Tenure: 0yrs
Hella Kohlhof
Chief Scientific Officer
- Tenure: 2.8yrs
Jessica Breu
Manager IR and Communications
- Tenure: 0yrs
Sanjay Patel
Chief Financial Officer
- Tenure: 0.3yrs
Board Members
Joerg Neermann (52yo)
- Tenure: 3.8yrs
Daniel Vitt (51yo)
CEO, President & Director
- Tenure: 2.8yrs
Vincent Ossipow (51yo)
Director
- Tenure: 2.8yrs
Duane Nash (48yo)
Chairman
- Tenure: 0.8yrs
Jan Van den Bossche
Director
- Tenure: 2.8yrs
Company Information
Immunic, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Immunic, Inc.
- Ticker: IMUX
- Exchange: NasdaqCM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$85.088m
- Shares outstanding: 10.09m
- Website: https://www.immunic-therapeutics.com
Number of Employees
Location
- Immunic, Inc.
- 11440 West Bernardo Court
- Suite 300
- San Diego
- California
- 92127
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IMUX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Apr 2019 |
| 10VA | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2019 |
Biography
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative coliti ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 00:41 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.